RLMD Stock Price, Relmada Therapeutics Inc Quote, Chart

Market Summary

USD3.41-0.08

Delayedas of 17 May 2024, 02:48 pm

-2.29%

RLMD Stock Price

View Fullscreen

RLMD RSI Chart

RLMD Valuation

Market Cap

105.3M

Price/Earnings (Trailing)

-1.12

Price/Sales (Trailing)

18.74

Price/Free Cashflow

-2.19

RLMD Price/Sales (Trailing)

RLMD Profitability

Return on Equity

-130.89%

Return on Assets

-111.72%

Free Cashflow Yield

-45.76%

RLMD Fundamentals

RLMD Revenue

Revenue (TTM)

6.2M

RLMD Earnings

Earnings (TTM)

-94.3M

Earnings Growth (Yr)

17.07%

Earnings Growth (Qtr)

13.26%

Breaking Down RLMD Revenue

52 Week Range

2.364.09

(Low)(High)

Last 7 days

-8.7%

Last 30 days

-23.9%

Last 90 days

-37.9%

Trailing 12 Months

11.9%

How does RLMD drawdown profile look like?

RLMD Financial Health

Current Ratio

6.82

RLMD Investor Care

Shares Dilution (1Y)

0.25%

Diluted EPS (TTM)

-2.62

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	0
2022	0	0	0	6.2M
2020	0	0	818.3K	0
2019	0	0	0	0
2018	0	0	0	0
2017	0	96.4K	0	0
2014	66.0K	0	0	0
2013	6.5K	5.8K	5.1K	35.6K
2012	0	0	7.9K	7.2K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Relmada Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 31, 2024	ence chuck	bought	55,429	4.0548	13,670	ca and co
Jan 31, 2024	shenouda maged	bought	27,943	4.0645	6,875	chief financial officer
Jan 31, 2024	traversa sergio	bought	109,752	3.9968	27,460	chief executive officer
Jan 30, 2024	shenouda maged	bought	58,323	3.8882	15,000	chief financial officer
Jan 30, 2024	traversa sergio	bought	159,949	3.9013	40,999	chief executive officer
Jan 30, 2024	ence chuck	bought	56,052	3.8657	14,500	ca and co
Jan 29, 2024	ence chuck	bought	39,438	3.6517	10,800	ca and co
Jan 29, 2024	shenouda maged	bought	39,450	3.6528	10,800	chief financial officer
Jan 29, 2024	traversa sergio	bought	117,036	3.7106	31,541	chief executive officer
May 23, 2023	o'gorman cedric	bought	31,800	3.18	10,000	chief medical officer

Which funds bought or sold RLMD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	CANTOR FITZGERALD, L. P.	new	-	357,210	357,210	0.08%
May 15, 2024	Point72 Asset Management, L.P.	sold off	-100	-1,035,000	-	-%
May 15, 2024	D. E. Shaw & Co., Inc.	sold off	-100	-44,087	-	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-81.22	-1,227,190	328,030	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	new	-	549,830	549,830	-%
May 15, 2024	MARSHALL WACE, LLP	added	35.4	331,002	966,596	-%
May 15, 2024	Mariner, LLC	added	14.96	25,159	111,553	-%
May 15, 2024	TWO SIGMA ADVISERS, LP	reduced	-0.64	157,668	1,516,830	-%
May 15, 2024	Engineers Gate Manager LP	new	-	63,645	63,645	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	298	35,226	45,365	-%

Are Funds Buying or Selling RLMD?

Are funds buying RLMD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RLMD

No. of Funds

Unveiling Relmada Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 06, 2024	perceptive advisors llc	0.0%	0	SC 13G/A
Feb 14, 2024	deep track capital, lp	6.79%	2,044,507	SC 13G/A
Feb 14, 2024	rtw investments, lp	0%	0	SC 13G/A
Feb 13, 2024	vanguard group inc	4.35%	1,310,805	SC 13G/A
Jul 07, 2023	blackrock inc.	2.0%	605,254	SC 13G/A
Feb 14, 2023	rtw investments, lp	6.9%	2,067,824	SC 13G/A
Feb 14, 2023	ra capital management, l.p.	0%	0	SC 13G/A
Feb 14, 2023	citadel advisors llc	0.1%	6	SC 13G/A
Feb 14, 2023	point72 asset management, l.p.	0%	0	SC 13G/A
Feb 14, 2023	biotechnology value fund l p	-	0	SC 13G/A

Recent SEC filings of Relmada Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 08, 2024	10-Q	Quarterly Report
Apr 09, 2024	DEFA14A	DEFA14A
Apr 09, 2024	DEF 14A	DEF 14A
Mar 19, 2024	8-K	Current Report
Mar 19, 2024	10-K	Annual Report
Mar 06, 2024	SC 13G/A	Major Ownership Report
Feb 20, 2024	144	Notice of Insider Sale Intent
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 13, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Relmada Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

Relmada Therapeutics Inc News

Latest updates

Relmada Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2020Q3	2020Q2	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2	2014Q1	2013Q4	2013Q3	2013Q2
Revenue	-	-	-	-	-	5,361,518	363,300	404,004	37,916	13,110	-	-	-	-	-	-	-	-	-	-	-	634
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-3.00	164	-	312
Operating Expenses	18.2%	26,829,320	22,692,638	26,026,726	28,153,609	38,702,420	17,183,582	12,757,202	3,707,410	4,135,702	2,702,004	3,478,984	2,411,230	1,930,123	-	-	-	-	-	-	-	-
S&GA Expenses	-1.3%	12,077,259	12,238,566	12,286,521	12,292,599	11,834,053	5,946,396	7,433,249	1,820,043	1,065,803	1,426,056	2,221,566	989,748	970,870	883,009	-	-	-	-	-	-	-
R&D Expenses	41.1%	14,752,061	10,454,072	13,740,205	15,861,010	26,868,367	11,237,186	5,323,953	1,887,367	3,069,899	1,275,948	1,257,418	1,421,482	959,253	-	-	-	-	-	-	-	-
Interest Expenses	-4.7%	1,259,226	1,321,441	1,363,406	1,207,631	1,114,527	363,300	404,004	37,916	13,110	15,939	-139,765	-650,322	-630,366	-397,111	-	-	-	-	-	-	-
Net Income	-14.4%	-25,165,158	-22,002,058	-25,302,954	-26,321,576	-37,944,365	-16,902,507	-11,118,441	-3,669,494	-4,122,592	-2,686,065	-7,129,310	-3,380,093	-3,349,932	-	-	-	-	-	-	-	-
Net Income Margin	11.5%	-16.02	-18.09	-20.92	-23.29	-25.47	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	11.9%	-10,249,714	-11,631,129	-13,273,269	-16,505,094	-35,882,900	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-13.5%	84.00	98.00	109	122	136	153	187	216	226	223	91.00	111	104	118	126	135	115	117	9.00	10.00	3.00
Current Assets	-13.5%	84.00	98.00	109	122	136	153	187	216	226	223	91.00	111	104	118	125	134	115	117	8.00	10.00	2.00
Cash Equivalents	-67.4%	1.00	4.00	7.00	14.00	29.00	5.00	43.00	37.00	45.00	44.00	11.00	5.00	4.00	2.00	8.00	14.00	12.00	36.00	8.00	9.00	2.00
Net PPE	-	-	-	-	-	-	-	-	-	-	-	-	-	452*	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	1.4%	12.00	12.00	-	-	10.00	12.00	-	-	15.00	15.00	14.00	14.00	13.00	13.00	-	-	-	1.00	3.00	3.00	2.00
Current Liabilities	1.4%	12.00	12.00	8.00	11.00	10.00	12.00	21.00	19.00	15.00	15.00	18.00	14.00	13.00	13.00	3.00	2.00	2.00	1.00	-	3.00	2.00
Shareholder's Equity	-15.6%	72.00	85.00	101	111	125	140	166	197	210	208	73.00	97.00	91.00	106	122	132	113	116	6.00	8.00	0.00
Retained Earnings	-3.9%	-582	-560	-535	-513	-488	-462	-424	-384	-344	-305	-270	-228	-201	-179	-158	-141	-130	-119	-115	-111	-107
Additional Paid-In Capital	1.3%	655	646	636	625	614	603	590	582	555	513	343	325	293	285	281	274	244	236	121	119	108
Shares Outstanding	0.2%	30.00	30.00	30.00	30.00	30.00	30.00	30.00	29.00	29.00	28.00	17.00	17.00	17.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	73.00	-	-	-	563	-	-	-	547	-	-	-	695	-	-	-	70.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-27.2%	-13,036	-10,249	-11,631	-13,273	-16,505	-35,882	-26,862	-21,626	-19,429	-37,660	-20,916	-17,211	-16,085	-6,928	-12,501	-4,953	-3,424	-3,879	-2,534	-3,667	-2,011
Share Based Compensation	-16.2%	8,295	9,894	11,393	11,170	11,354	11,626	8,343	12,295	11,931	18,361	8,014	8,268	5,851	3,191	5,245	7,303	5,039	1,609	758	403	395
Cashflow From Investing	29.9%	10,058	7,741	3,860	-1,151	40,004	-1,655	31,557	-140	-10,027	-91,182	27,511	-5,912	15,466	935	4,588	-16,338	-23,632	-	-	-	-
Cashflow From Financing	-	222	-	-	-	-	410	569	14,093	29,948	161,837	185	23,989	1,928	944	1,634	22,890	3,005	112,473	1,167	10,830	1,639

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

RLMD Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 13,305,306	$ 15,861,010
General and administrative	9,682,554	12,292,599
Total operating expenses	22,987,860	28,153,609
Loss from operations	(22,987,860)	(28,153,609)
Other income (expenses):
Interest/investment income, net	1,055,888	1,207,631
Realized gain (loss) on short-term investments	53,133	(666,708)
Unrealized gain on short-term investments	50,713	1,291,110
Total other income (expenses)	1,159,734	1,832,033
Net loss	$ (21,828,126)	$ (26,321,576)
Loss per common share – basic and diluted (in Dollars per share)	$ (0.72)	$ (0.87)
Weighted average number of common shares outstanding – basic and diluted (in Shares)	30,132,170	30,099,203

RLMD Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 1,335,018	$ 4,091,568
Short-term investments	82,277,687	92,232,292
Prepaid expenses	752,334	1,185,057
Total current assets	84,365,039	97,508,917
Other assets	43,125	43,125
Total assets	84,408,164	97,552,042
Commitments and Contingencies (See Note 6)
Current liabilities:
Accounts payable	5,189,101	3,506,009
Accrued expenses	7,172,732	8,688,791
Total current liabilities	12,361,833	12,194,800
Total liabilities	12,361,833	12,194,800
Stockholders’ Equity:
Preferred stock, $0.001 par value, 200,000,000 shares authorized, none issued and outstanding
Class A convertible preferred stock, $0.001 par value, 3,500,000 shares authorized, none issued and outstanding
Common stock, $0.001 par value, 150,000,000 shares authorized, 30,174,202 and 30,099,203 shares issued and outstanding, respectively	30,174	30,099
Additional paid-in capital	654,746,964	646,229,824
Accumulated deficit	(582,730,807)	(560,902,681)
Total stockholders’ equity	72,046,331	85,357,242
Total liabilities and stockholders’ equity	$ 84,408,164	$ 97,552,042

About Relmada Therapeutics Inc

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

CEO	Dr. Sergio Traversa M.B.A., MBA, Pharm.D., PharmD
WEBSITE	relmada.com
INDUSTRY	Biotechnology
EMPLOYEES	14

Relmada Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Relmada Therapeutics Inc? What does RLMD stand for in stocks?

RLMD is the stock ticker symbol of Relmada Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Relmada Therapeutics Inc (RLMD)?

As of Thu May 16 2024, market cap of Relmada Therapeutics Inc is 105.31 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RLMD stock?

You can check RLMD's fair value in chart for subscribers.

What is the fair value of RLMD stock?

You can check RLMD's fair value in chart for subscribers. The fair value of Relmada Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Relmada Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RLMD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Relmada Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether RLMD is over valued or under valued. Whether Relmada Therapeutics Inc is cheap or expensive depends on the assumptions which impact Relmada Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RLMD.

What is Relmada Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, RLMD's PE ratio (Price to Earnings) is -1.12 and Price to Sales (PS) ratio is 18.74. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RLMD PE ratio will change depending on the future growth rate expectations of investors.